CONTACT: Amgen, Thousand Oaks Christine Regan, 805-447-5476 (media) Arvind Sood, 805-447-1060 (investors)(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO) SOURCE Amgen
There's not much reason to be bullish on these stocks.
Regeneron has faced a lower stock price and patent wrangling. But the stock could be ready to rise again.
There could be a major windfall for Fortune 500 companies.